Wynnefield Capital »

Apellis Pharmaceuticals shares owned by Wynnefield Capital

Quarter-by-quarter ownership of Apellis Pharmaceuticals (APLS) shares owned by Wynnefield Capital from 13F filings

Historical chart of Wynnefield Capital investment in Apellis Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Apellis Pharmaceuticals held by Wynnefield Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Apellis Pharmaceuticals by Wynnefield Capital

Quarter filed Position value Share count Share price at filing
2023-12-31 $599k 10k 59.86
2023-09-30 $380k 10k 38.04

More positions owned by Wynnefield Capital

Dlh Holdings Corp Comm (DLHC)
Cadre Holdings Comm (CDRE)
Natures Sunshine Prods Comm (NATR)
Lifecore Biomedical Comm (LFCR)
Agnico Eagle Miners Comm (AEM)
Quest Resource Holding Corp Comm (QRHC)
Catalent Comm (CTLT)
Sunopta Comm (STKL)
S&w Seed Comm (SANW)
Techprecision Corp Comm (TPCS)
Great Lakes Dredge & Dock Comm (GLDD)
Telos Corporation Comm (TLS)
Global X Fds Global X Sil Comm (SIL)
Heritage Global Comm (HGBL)
Apellis Pharmaceuticals Comm (APLS)

View all positions for Wynnefield Capital

Top funds holding Apellis Pharmaceuticals

Wellington Management Company
EcoR1 Capital
venBio Select Advisor
Vanguard Group
Jennison Associates
Octagon Capital Advisors
Jpmorgan Chase & Co
T. Rowe Price Associates
Assenagon Asset Management
Logos Global Management
Boxer Capital
Artal Group
Citadel Advisors
Caption Management
Norges Bank Investment Management

View all funds holding Apellis Pharmaceuticals